Therachon completes cross-border acquisition of GLyPharma Therapeutic

On Oct. 9, 2018, Therachon AG announced the acquisition of GLyPharma Therapeutic Inc. for an undisclosed amount.

Therachon is a clinical-stage global biotechnology company based in Basel, Switzerland, which is focused on developing medicines for rare conditions with significant unmet medical needs. Until this transaction, GLyPharma was a Montréal-based Canadian Controlled Private Corporation funded by CTI Life Sciences Fund (CTILSF), a Montréal-based private VC Fund, Ferring and Fonds de solidarité FTQ, a Québec-based labor-sponsored Fund.

Gowling WLG supported and advised Therachon and its US counsel Cooley LLP on Canadian aspects of this acquisition with a team led by Lorne Segal and that included Shaela Rae, Ingrid Anton and Georgi Paskalev (corporate); Carole Chouinard (tax); and Josée Gervais (employment).